Dupixent from Sanofi S.A. - eczema injection that reshapes daily routines

Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 04:28. Details in the imprint.

The Dupixent prefilled pen from Sanofi S.A. sits cold in the palm before an injection, a slim white and green device that many eczema patients now keep next to their toothbrush on the bathroom shelf. It is one of Sanofi’s key biologic therapies for inflammatory skin disease and asthma.

How Dupixent works

Dupixent is a monoclonal antibody designed to block the signalling of interleukin-4 and interleukin-13, two central drivers of type 2 inflammation in atopic dermatitis and asthma. By targeting this pathway, the drug aims to reduce redness, itching and the cascade of immune responses that sustain chronic flare-ups.

Patients or caregivers inject Dupixent subcutaneously, typically into the thigh or abdomen, using a prefilled syringe or pen device that clicks when the dose is delivered and leaves only a mild sting at the injection site. The dosing schedule depends on age, weight and indication, with maintenance injections usually every two weeks after a loading dose.

What users notice day to day

For many adults with moderate to severe atopic dermatitis, one of the first changes is waking up without sheets dusted in skin flakes and without the constant urge to scratch until bleeding. The skin tends to feel less raw, sleep improves and daily routines shift away from endless topical creams toward timed injections.

Parents of pediatric patients have described the quiet moment just before the pen clicks as the emotional pivot, trading their child’s fear of another sleepless night for a structured treatment ritual. In interviews, Sanofi’s chief executive Paul Hudson has repeatedly pointed to Dupixent’s impact on quality of life as a strategic pillar for the company’s specialty care portfolio.

Indications and where it helps

Dupixent is approved in many markets for adults, adolescents and children with moderate to severe atopic dermatitis who are candidates for systemic therapy and whose disease is not adequately controlled by topical treatments. It is also indicated for certain forms of asthma and chronic rhinosinusitis with nasal polyposis.

In asthma, pulmonologists use the drug in patients with type 2 inflammation who remain poorly controlled despite medium to high dose inhaled corticosteroids and additional controllers. For these patients, fewer exacerbations and reduced oral steroid use are core treatment goals, and biologics like Dupixent sit alongside other targeted agents as part of step-up therapy.

Dosing, formats and handling

Sanofi supplies Dupixent in different strengths, with prefilled syringes and pens designed so that patients can self-administer after training by a nurse or physician. The device casing is smooth and rounded, intentionally avoiding sharp edges so that the moment of injection feels as unobtrusive as possible.

Storage requirements are strict: the pens must be kept refrigerated, protected from light and not frozen. Before injection, patients are typically instructed to let the device come to room temperature for around half an hour, which avoids the sharper sting that a cold biologic can cause under the skin.

Where it falls short

Dupixent does not work for every patient, and even responders may see only partial relief, with some residual itching or localised lesions. Adverse reactions can include injection-site reactions, conjunctivitis and other eye symptoms, which dermatologists and allergists now monitor routinely when starting therapy.

The need for ongoing injections and regular follow-up visits also makes the regimen demanding for families juggling school, work and travel, especially when multiple children or caregivers require biologic therapy. Some patients still describe the weekly or bi-weekly preparation as a mental burden despite the clinical benefits.

Pricing, access and competition

Biologic therapies like Dupixent are priced at a premium relative to topical corticosteroids or conventional systemic drugs, reflecting complex manufacturing and targeted mechanisms. In many European markets and in the United States, access depends heavily on reimbursement decisions and prior authorisation processes, which can delay the start of therapy.

Competing treatments include other biologics and small-molecule JAK inhibitors, which offer oral dosing rather than injections but carry their own benefit-risk balances and safety monitoring requirements. For prescribers, choice often hinges on patient age, comorbidities, disease severity, contraindications and individual preferences around route of administration.

Home market availability

Dupixent is part of Sanofi’s global portfolio and is marketed in major regions including Europe and North America through specialist physicians such as dermatologists, allergists and pulmonologists. Distribution typically runs via hospital pharmacies and specialist retail pharmacies rather than general over-the-counter channels.

In France, where Sanofi has deep roots, the biologic is embedded in standard care pathways for eligible patients, with reimbursement frameworks shaping uptake and long-term adherence. Specialist centres frequently run dedicated clinics for atopic dermatitis and severe asthma, where biologic initiation and monitoring follow structured protocols.

Context and stock reference

Dupixent sits at the centre of Sanofi’s shift toward higher-margin specialty medicines, alongside other immunology and neurology assets, and it is a recurring focus in presentations by CEO Paul Hudson when outlining growth priorities. Overall, Sanofi shares (ISIN FR0000120578) trade primarily on Euronext Paris, where clinical news and new indications for Dupixent regularly feed into investor narratives even when day-to-day price moves are modest.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | FR0000120578 | SANOFI | boerse | 69649331 | bgmi